Rediscovering the octapeptins

Tony Velkov, Kade D Roberts, Jian Li

Research output: Contribution to journalReview ArticleResearchpeer-review

14 Citations (Scopus)

Abstract

Covering: 1975 up to the end of 2016 

The decline in the discovery and development of novel antibiotics has resulted in the emergence of bacteria that are resistant to almost all available antibiotics. Currently, polymyxin B and E (colistin) are being used as the last-line therapy against life-threatening infections, unfortunately resistance to polymyxins in both the community and hospital setting is becoming more common. Octapeptins are structurally related non-ribosomal lipopeptide antibiotics that do not exhibit cross-resistance with polymyxins and have a broader spectrum of activity that includes Gram-positive bacteria. This makes them a precious and finite resource for the development of new antibiotics against these problematic polymyxin-resistant Gram-negative pathogens, in particular Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. This review surveys the progress in understanding octapeptin chemistry, mechanisms of antibacterial activity and biosynthesis. With the lack of cross-resistance and their broad antibacterial activity, the octapeptins represent ideal candidates for the development of a new generation of polymyxin-like lipopeptide antibiotics targeting polymyxin-resistant 'superbugs'.

Original languageEnglish
Pages (from-to)295-309
Number of pages15
JournalNatural Product Reports
Volume34
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Cite this

Velkov, Tony ; Roberts, Kade D ; Li, Jian. / Rediscovering the octapeptins. In: Natural Product Reports. 2017 ; Vol. 34, No. 3. pp. 295-309.
@article{7391417af67841eb93727a7562a15e37,
title = "Rediscovering the octapeptins",
abstract = "Covering: 1975 up to the end of 2016 The decline in the discovery and development of novel antibiotics has resulted in the emergence of bacteria that are resistant to almost all available antibiotics. Currently, polymyxin B and E (colistin) are being used as the last-line therapy against life-threatening infections, unfortunately resistance to polymyxins in both the community and hospital setting is becoming more common. Octapeptins are structurally related non-ribosomal lipopeptide antibiotics that do not exhibit cross-resistance with polymyxins and have a broader spectrum of activity that includes Gram-positive bacteria. This makes them a precious and finite resource for the development of new antibiotics against these problematic polymyxin-resistant Gram-negative pathogens, in particular Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. This review surveys the progress in understanding octapeptin chemistry, mechanisms of antibacterial activity and biosynthesis. With the lack of cross-resistance and their broad antibacterial activity, the octapeptins represent ideal candidates for the development of a new generation of polymyxin-like lipopeptide antibiotics targeting polymyxin-resistant 'superbugs'.",
author = "Tony Velkov and Roberts, {Kade D} and Jian Li",
year = "2017",
month = "3",
day = "1",
doi = "10.1039/c6np00113k",
language = "English",
volume = "34",
pages = "295--309",
journal = "Natural Product Reports",
issn = "0265-0568",
publisher = "The Royal Society of Chemistry",
number = "3",

}

Rediscovering the octapeptins. / Velkov, Tony; Roberts, Kade D; Li, Jian.

In: Natural Product Reports, Vol. 34, No. 3, 01.03.2017, p. 295-309.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Rediscovering the octapeptins

AU - Velkov, Tony

AU - Roberts, Kade D

AU - Li, Jian

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Covering: 1975 up to the end of 2016 The decline in the discovery and development of novel antibiotics has resulted in the emergence of bacteria that are resistant to almost all available antibiotics. Currently, polymyxin B and E (colistin) are being used as the last-line therapy against life-threatening infections, unfortunately resistance to polymyxins in both the community and hospital setting is becoming more common. Octapeptins are structurally related non-ribosomal lipopeptide antibiotics that do not exhibit cross-resistance with polymyxins and have a broader spectrum of activity that includes Gram-positive bacteria. This makes them a precious and finite resource for the development of new antibiotics against these problematic polymyxin-resistant Gram-negative pathogens, in particular Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. This review surveys the progress in understanding octapeptin chemistry, mechanisms of antibacterial activity and biosynthesis. With the lack of cross-resistance and their broad antibacterial activity, the octapeptins represent ideal candidates for the development of a new generation of polymyxin-like lipopeptide antibiotics targeting polymyxin-resistant 'superbugs'.

AB - Covering: 1975 up to the end of 2016 The decline in the discovery and development of novel antibiotics has resulted in the emergence of bacteria that are resistant to almost all available antibiotics. Currently, polymyxin B and E (colistin) are being used as the last-line therapy against life-threatening infections, unfortunately resistance to polymyxins in both the community and hospital setting is becoming more common. Octapeptins are structurally related non-ribosomal lipopeptide antibiotics that do not exhibit cross-resistance with polymyxins and have a broader spectrum of activity that includes Gram-positive bacteria. This makes them a precious and finite resource for the development of new antibiotics against these problematic polymyxin-resistant Gram-negative pathogens, in particular Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. This review surveys the progress in understanding octapeptin chemistry, mechanisms of antibacterial activity and biosynthesis. With the lack of cross-resistance and their broad antibacterial activity, the octapeptins represent ideal candidates for the development of a new generation of polymyxin-like lipopeptide antibiotics targeting polymyxin-resistant 'superbugs'.

UR - http://www.scopus.com/inward/record.url?scp=85015978851&partnerID=8YFLogxK

U2 - 10.1039/c6np00113k

DO - 10.1039/c6np00113k

M3 - Review Article

VL - 34

SP - 295

EP - 309

JO - Natural Product Reports

JF - Natural Product Reports

SN - 0265-0568

IS - 3

ER -